CN105738492B - The method of impurity content in LC MS/MS combination measure Lapatinibs - Google Patents
The method of impurity content in LC MS/MS combination measure Lapatinibs Download PDFInfo
- Publication number
- CN105738492B CN105738492B CN201410755906.4A CN201410755906A CN105738492B CN 105738492 B CN105738492 B CN 105738492B CN 201410755906 A CN201410755906 A CN 201410755906A CN 105738492 B CN105738492 B CN 105738492B
- Authority
- CN
- China
- Prior art keywords
- compound
- solution
- mobile phase
- chloroanilines
- methylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000012535 impurity Substances 0.000 title claims abstract description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 title claims abstract description 10
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims abstract description 48
- 229960004891 lapatinib Drugs 0.000 claims abstract description 48
- 238000001514 detection method Methods 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 36
- AMYYUKGKCJKCBI-UHFFFAOYSA-N 2-methylsulfonylethanamine;hydrochloride Chemical compound Cl.CS(=O)(=O)CCN AMYYUKGKCJKCBI-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 238000012360 testing method Methods 0.000 claims abstract description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 78
- 239000000243 solution Substances 0.000 claims description 61
- 150000002500 ions Chemical class 0.000 claims description 50
- 239000000523 sample Substances 0.000 claims description 43
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 25
- 229960004194 lidocaine Drugs 0.000 claims description 25
- 238000010828 elution Methods 0.000 claims description 19
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical class NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 claims description 13
- 239000013558 reference substance Substances 0.000 claims description 13
- 238000004949 mass spectrometry Methods 0.000 claims description 11
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 10
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000012417 linear regression Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000011088 calibration curve Methods 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 3
- SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical class CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000012488 sample solution Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- IWXRPVHRDWXIEA-UHFFFAOYSA-N azanium formate hydrate Chemical compound [NH4+].O.[O-]C=O IWXRPVHRDWXIEA-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000003908 quality control method Methods 0.000 abstract description 3
- XWXGUSLBEVUMLA-UHFFFAOYSA-N FC1=CC=CC(CONC=2C=C(Cl)C=CC=2)=C1 Chemical class FC1=CC=CC(CONC=2C=C(Cl)C=CC=2)=C1 XWXGUSLBEVUMLA-UHFFFAOYSA-N 0.000 abstract 2
- 238000012113 quantitative test Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 160
- 239000012071 phase Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 7
- 238000004445 quantitative analysis Methods 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000013062 quality control Sample Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940126600 bulk drug product Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005464 sample preparation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Abstract
The invention provides LC MS/MS to be combined the method for 4 (3 fluorobenzyloxy) 3 chloroanilines and 2 (methylsulfonyl) ethylamine hydrochloride impurity contents in detection Lapatinib.Pass through method of the present invention, can fast and effeciently detect 4 (3 fluorobenzyloxy) 3 chloroanilines and 2 (methylsulfonyl) ethylamine hydrochloride impurity in Lapatinib bulk drug, and can simultaneous quantitative test and analyze the contents of this 2 kinds of impurity.Using method of the present invention, testing result is accurately and reliably, easy to operate, and quickly, specificity is strong, reproducible, and noresidue effect, the quality control available for the production of Lapatinib medicine.
Description
Technical field
The present invention relates to Pharmaceutical Analysis technical field, in particular it relates to which LC-MS/MS combination detection antineoplastics draw pa to replace
The method of impurity content in Buddhist nun.
Background technology
Lapatinib is that one kind can target human epidermal growth factor acceptor (EGFR) and human epidermal growth factor receptor simultaneously
The small molecule kinase inhibitors of body -2 (HER2), are developed by GSK companies, U.S. FDA approval are obtained in March, 2007, for joining
Share medicine：Capecitabine treatment overexpression HER2 late period or metastatic breast cancer is shared, Letrozole is shared and treats excessive table
Up to HER2, the metastatic breast cancer menopausal women of hormone receptor positive.
4- (3- fluorobenzyloxies) 3- chloroanilines (compound 4) and 2- (methylsulfonyl) ethylamine hydrochloride (compound 9) are respectively
It is that two kinds of productions for preparing Lapatinib bulk drug are replaced with intermediate feed (both structures see below formula), drawing pa usually finally
A small amount of compound 4 and the impurity of compound 9 can be contained in Buddhist nun's finished product bulk drug, in order to improve the quality of Lapatinib and stably
Property and reduce poisonous side effect of medicine for clinic Lapatinib, therefore need to enter compound 4 and compound 9 in production
Row content analysis is determined, and the content of compound 4 and the impurity of compound 9 is limited the quantity in Lapatinib bulk drug.
In the prior art, the method that Light absorbing impurty is only carried out for compound 4, but currently without for compound 4
The method for carrying out assay simultaneously with compound 9 is seen in report, thus, the impurity content on Lapatinib analyzes measure side
Method still has much room for improvement.
The content of the invention
It is contemplated that at least solves one of technical problem in correlation technique to a certain extent.Therefore, the present invention
One purpose is to propose a kind of result accurately and reliably, and easy, quickly, specificity is strong, reproducible, can Simultaneous Quantitative Analysis
LC-MS/MS (liquid chromatography-mass spectrography/mass spectrum) the combination detection methods of the content of compound 4 and compound 9, for Lapatinib medicine
The quality control of thing production.
The present invention is the following discovery based on inventor and completed：
For inventor in the drug standards for formulating Lapatinib bulk drug, the content limit of the impurity of compound 4 is not higher than 4
μ g/1g (i.e. 4ppm), the content limit of the impurity of compound 9 is the common high performance liquid chromatography detectionization not higher than 0.02%
The test limit of compound 4 is very low, can only determine the impurity of 0.1% and the above.Compound 9 with liquid phase because that without UV absorption, can not be surveyed
It is fixed.Although inventor attempts to be detected with evaporative light-scattering, its test limit is very low, can only determine 2% and the above it is miscellaneous
Matter.Inventor is former using C8 (sunfire C850*4.6mm, 5 μm) chromatographic column optimization analysis Lapatinib in research process
Expect medicine and compound 4, the chromatographic condition of compound 9, by the use of methanol (B)-water (A) as mobile phase, sampling volume is 10.0 μ L,
Found in experimentation, in gradient condition as shown in table 1 and in such chromatographic column, compound 4 and drawing pa replace
The reservation of Buddhist nun's bulk drug is preferable, but compound 9 shows good retention behavior (compound 9 is substantially in dead time position
Appearance is put, the dead volume under the conditions of being somebody's turn to do is about 0.5mL, and the appearance time of compound 9 is 1.5min).
Table 1：Sunfire C8 gradient condition
| Time (min) | Mobile phase B (%) | Flow velocity (ml/min) |
| 0 | 30 | 0.3 |
| 0.4 | 30 | 0.3 |
| 2.0 | 60 | —— |
| 6.0 | 95 | 0.8 |
| 9.0 | 95 | 0.8 |
| 9.1 | 30 | 0.3 |
| 11 | 30 | 0.3 |
The reservation of compound is too weak during LC-MS/MS analyses, is easily disturbed by the big compound of other polarity,
So as to influence the quantitative accuracy of compound.In order to accurate quantitative analysis compound 4 and compound 9 simultaneously, need to strengthen
The reservation of compound 9.So in order to strengthen the reservation of compound 9, this research carries out method exploitation under existing experiment condition,
It is intended to establish a simplicity, quickly, specificity is strong, and the Light absorbing impurty of compound 4 and compound 9 is analyzed suitable for Lapatinib
Method.
In research process, by a large amount of repetition tests, inventor is had found using Aquasil C18 chromatographic columns, Mobile phase B
When (organic phase) uses acetonitrile, effect is preferable.
Further, in order that compound 4 and compound 9 have certain reservation on a column, and without residual effect
(it should remain, i.e., chromatographic peak can occur in corresponding appearance time in the blank sample (solvent) after enriched sample is injected.
It is general to require under remaining no more than quantifying if compound has residual to influence quantitative accuracy in quantitative analysis process
Limit 20%), the present inventor passes through extremely hard and bitter effort and experimental study, it has unexpectedly been found that using Aquasil
C18 chromatographic columns, using the gradient condition shown in table 2, organic phase (B) is acetonitrile, and aqueous phase (A) is water (ammonium formate containing 5mM), sample introduction
Effect is preferable when volume is 5.00 μ L, and typical chromatogram is as shown in figure 1, Lapatinib, compound 4, compound 9 and benefit
The appearance time of cacaine (internal standard) is respectively 2.09min, 0.54min, 0.81min, 1.21min.Due to bulk drug concentration compared with
Height, so switched it to by six-way valve from 1.5 minutes into waste liquid bottle, in order to avoid influence mass spectrum.
Table 2：Aquasil C18 gradient condition
| Time (min) | Mobile phase B (%) | Flow velocity (ml/min) |
| 0 | 55 | 0.6 |
| 1.0 | 55 | 0.6 |
| 1.5 | 95 | 0.6 |
| 2.5 | 95 | 0.6 |
| 2.6 | 55 | 0.6 |
| 3.6 | 55 | 0.6 |
Therefore, the invention provides one kind to detect 4- (3- fluorobenzyloxies) 3- chloroanilines and 2- (MSMs in Lapatinib
Base) ethylamine hydrochloride impurity content method.According to an embodiment of the invention, this method is to utilize LC-MS/MS combinations detection side
What method was carried out.
According to an embodiment of the invention, wherein chromatographic condition is：Chromatographic column is using octadecyl silane as filler；Stream
It is dynamic to be mutually made up of mobile phase A and Mobile phase B, wherein, the mobile phase A is formic acid aqueous ammonium, and the Mobile phase B is acetonitrile；
Type of elution is gradient elution.Thus, quantitative inspection can be carried out to the compound 4 in Lapatinib bulk drug and compound 9 simultaneously
Survey, compound 4 and compound 9 have preferable reservation, and simple to operate, convenient and swift.
According to an embodiment of the invention, wherein chromatographic condition is：Using octadecyl silane as filler；Mobile phase by
Mobile phase A and Mobile phase B composition, wherein, the mobile phase A is the formic acid aqueous ammonium that concentration is 5 mM/ls, the stream
Dynamic phase B is acetonitrile；Flow velocity 0.5ml/min~0.7ml/min；25 degrees Celsius~35 degrees Celsius of column temperature；The μ l of sample size 5, detect ripple
Long 261nm, type of elution are gradient elution.Inventor has found, using this method of the present invention, can fast and effectively detect drawing
Pa replace Buddhist nun's bulk drug in impurity, and can Simultaneous Quantitative Analysis compound 4 and compound 9, testing result accurately and reliably, operation letter
Just, quickly, specificity is strong, reproducible.
According to an embodiment of the invention, wherein Mass Spectrometry Conditions are：Ion gun is ESI sources, is detected using positive ion mode, be more
Weight reaction monitoring MRM patterns；The detection ion pair of Lapatinib is m/z 581-365；4- (3- fluorobenzyloxies) 3- chloroanilines
Detection ion pair be m/z 252-143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/z 124-79；And benefit card
The detection ion pair of cause is m/z 235-86；Source parameters is：Gas curtain gas (CUR) 30psi；Ion injection electric (IS)
5500V；550 DEG C of temperature (TEM)；Ion gun GS150psi；Ion gun GS2260psi.Thereby, it is possible to accurate quantitative analysis detection to draw
Pa replaces the content of the impurity compound 4 and compound 9 in Buddhist nun's bulk drug, and it is limited the quantity, and high sensitivity, accuracy is good,
It is reproducible.
According to an embodiment of the invention, the column temperature of chromatographic column is 25 degrees Celsius~35 degrees Celsius.Thus, it is simultaneously fixed to be advantageous to
Measure analysis of compounds 4 and compound 9, Detection results too high or too low for temperature are undesirable.
According to an embodiment of the invention, the flow velocity of the mobile phase is 0.5ml/min~0.7ml/min.Thus, compound
4th, the separating effect of compound 9 and Lapatinib is preferable, and detection time is short, and detection efficiency is high.
According to an embodiment of the invention, in the mobile phase A, the concentration of the ammonium formate is 5 mM/ls.Thus,
The good separating effect of compound 4, compound 9 and Lapatinib, specificity is strong, and accuracy in detection is high.
According to an embodiment of the invention, the condition of the gradient elution is：
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 40~50 | 60~50 |
| 1.0 | 40~50 | 60~50 |
| 1.5 | 2~8 | 98~92 |
| 2.5 | 2~8 | 98~92 |
| 2.6 | 40~50 | 60~50 |
| 3.6 | 40~50 | 60~50 |
Thus, compound 4, compound 9 and Lapatinib do not have residual effect, the accurate good, high sensitivity of testing result.
According to an embodiment of the invention, the chromatographic column is C18 chromatographic columns, and preferably described chromatographic column is Thermo
Aquasil C18 (50*2.1mm, 5 μm) HPLC chromatogram post.Thus, compound 4 and compound 9 have preferable reservation, can
Quantitative analysis effectively is carried out to compound 4 and compound 9 simultaneously, and it is simple to operate, the degree of accuracy is high, reproducible.
According to an embodiment of the invention, method of the present invention comprises the following steps：
(1) chromatographic condition：Using octadecyl silane as filler；The mobile phase A is that concentration is 5 mM/ls
Formic acid aqueous ammonium, the Mobile phase B is acetonitrile；Flow velocity 0.5ml/min~0.7ml/min；Column temperature 25 degrees Celsius~35 is taken the photograph
Family name's degree；The μ l of sample size 5, Detection wavelength 261nm, are carried out according to the following table gradient elution：
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 40~50 | 60~50 |
| 1.0 | 40~50 | 60~50 |
| 1.5 | 2~8 | 98~92 |
| 2.5 | 2~8 | 98~92 |
| 2.6 | 40~50 | 60~50 |
| 3.6 | 40~50 | 60~50 |
(2) Mass Spectrometry Conditions：Ion gun is ESI sources, is detected using positive ion mode, multiple reaction monitoring MRM patterns； 4-
The detection ion pair of (3- fluorobenzyloxies) -3- chloroanilines is m/z:252—143；The detection ion pair of 2- (methylsulfonyl) ethamine
For m/z:124—79；Target detection ion pair is m/z in lidocaine:235—86；
Source parameters is：
Gas curtain gas 30psi；
Ion injection electric 5500V；
550 DEG C of temperature；
Ion gun GS1 50psi；
Ion gun GS2 60psi,
(3) Lapatinib bulk drug and lidocaine internal standard are weighed respectively, use acetonitrile：Water (volume ratio 4：1) it is configured to draw
Pa is 5.00mg/mL storing solution for Buddhist nun's raw material concentration, then uses acetonitrile：Water (volume ratio 1：1) storing solution is diluted to
The need testing solution, in the need testing solution, the concentration of the Lapatinib bulk drug is 0.500mg/mL, the profit
Target concentration is 1.00ng/mL in more cacaines；
(4) the μ l of the need testing solution 5 injections LC-MS LC-MS instrument is drawn, according to the chromatostrip described in (1) and (2)
Part and Mass Spectrometry Conditions are detected, and record chromatogram；
(5) according to chromatogram resulting in step (4), calculated using calibration curve method in the Lapatinib bulk drug
The content of 4- (3- fluorobenzyloxies) -3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride.
Inventor has found, using this method of the present invention, can carry out quantitative analysis to compound 4 and compound 9 simultaneously,
And then the impurity in Lapatinib bulk drug is limited the quantity, and it is simple to operate, high sensitivity, reproducible, specificity is strong.
According to an embodiment of the invention, the calibration curve method comprises the following steps：
(a) 4- (3- fluorobenzyloxies) -3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride are dissolved in into volume ratio respectively is
4：In 1 acetonitrile-aqueous solution, the concentration for obtaining 4- (3- fluorobenzyloxies) -3- chloroanilines is 1.00mg/mL the first reference substance
The concentration of storing solution and 2- (methylsulfonyl) ethylamine hydrochloride is the second reference substance storing solution with 2.00mg/mL；
(b) it is 1 using volume ratio：1 acetonitrile-aqueous solution is by the first reference substance storing solution and second reference substance
Storing solution is diluted, and is obtained containing 10.0 μ g/mL 4- (3- fluorobenzyloxies) -3- chloroanilines and 500 μ g/mL 2- (MSMs
Base) ethylamine hydrochloride mixing intermediate solution 1；
(c) the mixing intermediate solution 1 is diluted 100 times, obtains mixing intermediate solution 2；
(d) the mixing intermediate solution 2 is diluted 10 times, obtains mixing intermediate solution 3；
(e) lidocaine internal standard is dissolved in volume ratio for 1：In 1 acetonitrile-aqueous solution, lidocaine internal standard concentration is obtained
For 0.200mg/mL internal standard storing solution, then it is 20.0ng/mL that the internal standard deposit is also diluted into lidocaine internal standard concentration
Internal standard intermediate solution；
(f) using mixing intermediate solution 2, the mixing intermediate solution 3 and the internal standard intermediate solution, according to following table
Prepare standard curve sample：
(g) the μ l of standard curve sample solution 5 processed are drawn and is injected separately into LC-MS LC-MS instrument, according to (1) and (2)
Described chromatographic condition and Mass Spectrometry Conditions is detected, and records chromatogram；
(h) using the ratio of 4- (3- fluorobenzyloxies) -3- chloroanilines and internal standard peak area as ordinate, 4- (3- fluorobenzene first
Epoxide) -3- chloroanilines concentration for abscissa carry out linear regression, make the first standard curve, with 2- (methylsulfonyl) ethylamine salt
The ratio of hydrochlorate and internal standard peak area is ordinate, and the concentration of 2- (methylsulfonyl) ethylamine hydrochloride is linearly returned for abscissa
Return, make the second standard curve；
(i) by 4- (3- fluorobenzyloxies) -3- chloroanilines, 2- (methylsulfonyl) second in chromatogram resulting in step (4)
Target peak area substitutes into first standard curve and described respectively in target lidocaine in amine hydrochlorate and lidocaine
Second standard curve, 4- (3- fluorobenzyloxies) -3- chloroanilines and 2- (MSMs in the Lapatinib bulk drug is calculated
Base) ethylamine hydrochloride content.
Using above-mentioned standard curve method, fast and accurately compound 4 and compound 9 can be quantified, and accurately
Reliably, it is simple and convenient.
Beneficial effects of the present invention：
The method of impurity in detection antineoplastic Lapatinib is combined by LC-MS/MS of the present invention, can be quick
The compound 4 and the impurity of compound 9 in Lapatinib bulk drug are effectively detected, and can simultaneous quantitative detection and analysis compound 4
With the content of compound 9.Determination method is combined using LC-MS/MS of the present invention, testing result accurately and reliably, is grasped
Make simplicity, quickly, specificity is strong, reproducible, and noresidue effect.LC-MS/MS combinations measure Lapatinib of the present invention
The method of middle impurity content, the quality control available for the production of Lapatinib medicine.
Brief description of the drawings
Fig. 1 shows Lapatinib, compound 4, the typical chromatogram of compound 9 and internal standard lidocaine appearance time
Figure；
Fig. 2 shows according to an embodiment of the invention, compound 4, the full scan mass spectrogram of compound 9 and Lapatinib；
Fig. 3 shows according to an embodiment of the invention, the second order mses figure of compound 4；
Fig. 4 shows according to an embodiment of the invention, the second order mses figure of compound 9；
Fig. 5 shows according to an embodiment of the invention, the second order mses figure of Lapatinib；
Fig. 6 shows that according to an embodiment of the invention the specificity of compound 4 (10.0ng/ml) investigates chromatogram；
Fig. 7 shows that according to an embodiment of the invention the specificity of compound 9 (500ng/ml) investigates chromatogram；
Fig. 8 shows that according to an embodiment of the invention the specificity of internal standard lidocaine (1.00ng/ml) investigates chromatogram
Figure；
Fig. 9 shows according to an embodiment of the invention, the residual effect chromatogram of compound 4 and compound 9.
Embodiment
Embodiments of the invention are described below in detail.The embodiments described below is exemplary, is only used for explaining this hair
It is bright, and be not considered as limiting the invention.Unreceipted particular technique or condition in embodiment, according to text in the art
Offer described technology or condition or carried out according to product description.Agents useful for same or the unreceipted production firm person of instrument,
For the conventional products of acquisition purchased in market can be passed through.
Embodiment 1
Using mass spectrograph (AB Sciex Q-Trap 4500) respectively to compound 4, compound 9 and Lapatinib just from
Full scan (Q1Scan) is done under subpattern, finds corresponding parent ion, then corresponding two level is done to parent ion, selection intensity is higher
Daughter ion see Fig. 2 to Fig. 5 as final detection ion, collection of illustrative plates.Last each compound selection intensity higher one from
Son is right, and optimizes corresponding parameter (source parameters, the parameter related to compound), the results are shown in Table 3 and table 4.
Table 3：Source parameters
| Polarity | Positive pole |
| Scan type | MRM |
| Gas curtain gas (CUR) | 30psi |
| Ion gun (GS1) | 50psi |
| Ion gun (GS2) | 60psi |
| Ion injection electric | 5500V |
| Temperature | 550℃ |
Table 4：The related parameter of compound
Embodiment 2
Utilize chromatographic column (the Synergi Hydro-RP, 50*3.0,4 μm of 5 types；Synergi Polar-RP 50*
3.0,4 μm；Aquasil C1850*2.1mm, 5 μm；Kromasil silica 50*3.0mm, 5 μm；Betasil silica-
10050*2.1mm 5 μm), using acetonitrile as Mobile phase B, with water (ammonium formate containing 5mM) for mobile phase A, respectively to compound 4, change
Compound 9 carries out LC-MS/MS detections, and records chromatogram.
As a result：
During using Hydro-RP chromatographic columns and Polar-RP chromatographic columns, compound 9 is in Hydro-RP, Polar-RP chromatographic columns
On do not retain substantially.
During using Aquasil C18 chromatographic columns, during using low organic phase (20% acetonitrile isocratic elution), compound 9 does not have
Retain, and compound 9 has certain reservation at high organic phase (95% acetonitrile isocratic elution).
During using Betasil silica-100 chromatographic columns and Kromasil silica chromatographic columns, the reservation of compound 9 compared with
By force, but compound 4 does not retain.
Therefore present invention preferably employs Aquasil C18 chromatographic columns.
Embodiment 3：Methodological study and sample analysis
It is that the limit of compound 9 is fixed two changes not higher than 0.02% not higher than 4ug/1g according to the limit of compound 4
The mark song scope of compound is respectively 0.200ng/ml -10.0ng/ml (compound 4), 10ng/ml -500ng/ml (compounds
9).Instrument and reagent
Reagent：Acetonitrile (Fisher), water, ammonium formate, Lapatinib bulk drug (14 batches), 4- (3- fluorobenzene methoxies
Base) -3- chloroaniline (lot numbers：120814), 2- (methylsulfonyl) ethylamine hydrochloride (lot number：20120521CMQA-1-MZP-01-
014)。
Instrument：Mass spectrum：AB Sciex Q-Trap 4500,
Efficient liquid phase：Shimadzu 20ACXR
(1) preparation of reference substance storing solution：Reference substance (compound 4, compound 9) is taken in right amount, with solvent (acetonitrile：Water=
4:1) dissolve, 1.00mg/ml storing solution is made.Then acetonitrile is used：Water (1:1) compound 4 is diluted to 10000ng/ml,
100ng/ml, 10.0ng/ml intermediate solution, compound 9 is diluted to 10000ng/ml, in 5000ng/ml, 500ng/ml
Between solution.
(2) preparation of inner mark solution：Take lidocaine internal standard appropriate, with (acetonitrile：Water=1:1) dissolve, be made
0.200mg/ml storing solution, then it is diluted to 20.0ng/ml intermediate solution.
(3) preparation of standard curve sample：Standard curve sample is prepared by table 5.
Table 5：Standard curve sample
(4) preparation of quality-control sample (QC)：Quality-control sample is prepared by table 6.
Table 6：Quality-control sample
(5) sample preparation
Precision weighs a certain amount of Lapatinib bulk drug, uses acetonitrile：Water (volume ratio 4:1) 1.00mg/ml is made in dissolving
Storing solution, then use acetonitrile：Water (volume ratio 1:1) 2.5 times are diluted, centrifuges 5 minutes (13000 revs/min), takes supernatant, i.e.,
, sample message is shown in Table 7.
Table 7：Sample message
(6) range of linearity
Standard curve sample is prepared by table 5, with the ratio between the peak area of analyte and interior target peak area for ordinate, analysis
The concentration of thing is abscissa, carries out linear regression operation.Compound 4 and compound 9 the two compounds are in corresponding scope
Linear relationship is good.
Regression equation is respectively：
Compound 4：Y=0.0416x+0.00195 (r=0.9986)；
Compound 9：Y=0.00416x+0.00175 (r=0.9986).
As a result show, the linear relationship in the range of 0.200-10.0ng/mL of compound 4 is good, compound 9 10.0-
Linear relationship is good in the range of 500ng/mL.
(7) veracity and precision (in a few days) is investigated
Quality-control sample is prepared by table 6, each concentration prepares 3 parts, investigates its degree of accuracy and precision (in a few days), the results are shown in Table
8.Shown according to result, the degree of accuracy of compound 4 and compound 9 is between 85% to 115%, and precision RSD is in ± 15% model
In enclosing.
Table 8：The degree of accuracy and precision
(8) specificity is investigated
Specificity means that under conditions of other compositions there may be used method energy Accurate Determining goes out measured object
Characteristic.Compound 4 and compound 9 are determined simultaneously in this method, is understood according to Fig. 6 to Fig. 8, compound 4 (10.0ng/ml), is changed
Do not interfered between compound 9 (500ng/ml) and internal standard lidocaine (1.00ng/ml).
(9) residual effect is investigated
In this experimentation, after having injected enriched sample (such as upper limit of quantification, ULOQ), two blank are continuously injected
Sample detects residual effect.As shown in figure 9, compound 4 and compound 9 do not remain under the chromatographic condition.
(9) sample analysis
After sample is prepared by table 7, sample introduction analysis, by the peak area of the compound 4 determined and compound 9 and internal standard peak face
Product calculates than substituting into standard curve, produces the concentration of compound 4 and compound 9 in sample (bulk drug).Then two are calculated
Content of the impurity in each batch of bulk drug.According to the rules, compound 4 is no more than 4 μ g/1g, and compound 9 is no more than 0.02%, meter
Calculation the results are shown in Table 9.As a result show, the content of compound 4 is all not less than 4 μ g/1g limit, compound in the sample of 14 batches
The 9 content also limit without departing from 0.02%.Compound 4 and compound 9 in the Lapatinib bulk drug product of 14 batches
In limit.
Table 9：Sample analysis result table
Embodiment 4
1. instrument and reagent
Reagent：Acetonitrile (Fisher), water, ammonium formate, Lapatinib bulk drug (3 batches), 4- (3- fluorobenzyloxies)-
3- chloroanilines (the lot number of compound 4：CM1101-130501-F1), 2- (methylsulfonyl) ethylamine hydrochloride (lot number of compound 9：
CM1101-130801-F1)。
Instrument：Mass spectrum：AB Sciex Q-Trap 4500, efficient liquid phase：Shimadzu 20ACXR
2. experiment content
2.1 chromatograms and Mass Spectrometry Conditions
Chromatographic condition is with system suitability using octadecyl silane as filler；Mobile phase by mobile phase A and
Mobile phase B forms, wherein, the mobile phase A is the formic acid aqueous ammonium that concentration is 5 mM/ls, and the Mobile phase B is second
Nitrile；Flow velocity 0.6ml/min；30 degrees Celsius of column temperature；The μ l of sample size 5, Detection wavelength 261nm, type of elution is gradient elution.According under
Table 10 carries out gradient elution：
Table 10
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 45 | 55 |
| 1.0 | 45 | 55 |
| 1.5 | 5 | 95 |
| 2.5 | 5 | 95 |
| 2.6 | 45 | 55 |
| 3.6 | 45 | 55 |
Connect and tested with triple level Four bar mass spectrographs, MRM patterns are monitored using multiple reaction：Impurity 4- (3- to be measured
Fluorobenzyloxy) the detection ion pairs of -3- chloroanilines is m/z:252—143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/
z:124—79；Target detection ion pair is m/z in lidocaine:235—86；Typical mass detector parameter is as follows：
Source parameters：
CUR：30psi,
IS：5500V,
TEM：550 DEG C,
GS1：50psi,
GS2：60psi.
2.2 sample preparation
It is that the limit of compound 9 is fixed two changes not higher than 0.02% not higher than 4 μ g/1g according to the limit of compound 4
The mark song scope of compound is respectively 0.200ng/mL -10.0ng/mL (compound 4), 10.0ng/mL -500ng/mL (compounds
9)。
(1) preparation of reference substance storing solution：Reference substance (compound 4, compound 9) is taken in right amount, with solvent (acetonitrile：Water=
4:1) dissolve, 1.00mg/mL, 2.00mg/mL storing solution is made；
(2) preparation of intermediate solution 1 is mixed：Use acetonitrile：Water (1:1) storing solution is diluted to containing 10.0 μ g/mL compounds
The mixing intermediate solution 1 of 4,500 μ g/mL compounds 9；
(3) preparation of intermediate solution 2 is mixed：Mixing intermediate solution 1 in (2) is diluted 100 times, makes into 100ng/mLization
Compound 4, the mixing intermediate solution 2 of 5000ng/mL compounds just；
(4) preparation of intermediate solution 3 is mixed：Mixing intermediate solution 2 in (3) is diluted 10 times, makes into 10.0ng/mLization
Compound 4, the mixing intermediate solution 3 of 500ng/mL compounds 9.
(5) preparation of inner mark solution：Take lidocaine reference substance appropriate, with (acetonitrile：Water=1:1) dissolve, be made
0.200mg/mL storing solution, then it is diluted to 20.0ng/mL intermediate solution.
(6) preparation of standard curve sample：Standard curve sample is prepared by table 11.
Table 11：Standard curve sample preparation table
(7) test sample is prepared：Weighing this product, appropriate (lot number is respectively：LT20140902), it is accurately weighed, use acetonitrile：Water
(4：1) 5.00mg/mL storing solutions are configured to, then use acetonitrile：Water (1：1) 0.500mg/mL solution (containing the internal standards to be measured are diluted to
1.00ng/mL)。
2.3 methodological study
2.3.1 it is linear to investigate：Standard curve sample is prepared by condition under " 2.2 " item.Compound 4 and compound 9 are carried out
Linear regression.As a result show, the linear relationship in the range of 0.200-10.0ng/mL of compound 4 is good, compound 9 10.0-
Linear relationship is good in the range of 500 ng/mL.
2.4 sample analysis
Test sample press " 2.2 " item under prepare after, sample introduction analysis, by the peak area of the compound 4 determined and compound 9 with
Internal standard peak area ratio is substituted into standard curve and calculated, and produces the concentration of compound 4 and compound 9 in sample (bulk drug).Then
Calculate content of two impurity in each batch of bulk drug.According to the rules, compound 4 is no more than 4 μ g/1g, and compound 9 is no more than
0.02%, result of calculation is shown in Table 12.Compound 4 and compound 9 are in limit in the Lapatinib bulk drug product of 3 batches
It is interior.
Table 12：Sample analysis result table
Embodiment 5
1. instrument and reagent
Reagent：Acetonitrile (Fisher), water, ammonium formate, Lapatinib bulk drug (3 batches), 4- (3- fluorobenzyloxies)-
3- chloroanilines (the lot number of compound 4：CM1101-130701-F2), 2- (methylsulfonyl) ethylamine hydrochloride (lot number of compound 9：
CM1101-130901-F2)。
Instrument：Mass spectrum：AB Sciex Q-Trap 4500, efficient liquid phase：Shimadzu 20ACXR
2. experiment content
2.1 chromatograms and Mass Spectrometry Conditions
Chromatographic condition is with system suitability using octadecyl silane as filler；Mobile phase by mobile phase A and
Mobile phase B forms, wherein, the mobile phase A is the formic acid aqueous ammonium that concentration is 5 mM/ls, and the Mobile phase B is second
Nitrile；Flow velocity 0.5ml/min；25 degrees Celsius of column temperature；The μ l of sample size 5, Detection wavelength 261nm, type of elution is gradient elution.According under
Table 13 carries out gradient elution：
Table 13
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 40 | 60 |
| 1.0 | 40 | 60 |
| 1.5 | 2 | 98 |
| 2.5 | 2 | 98 |
| 2.6 | 40 | 60 |
| 3.6 | 40 | 60 |
Connect and tested with triple level Four bar mass spectrographs, MRM patterns are monitored using multiple reaction：Impurity 4- (3- to be measured
Fluorobenzyloxy) the detection ion pairs of -3- chloroanilines is m/z:252—143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/
z:124—79；Target detection ion pair is m/z in lidocaine:235—86；Typical mass detector parameter is as follows：
Source parameters：
CUR：30psi,
IS：5500V,
TEM：550 DEG C,
GS1：50psi,
GS2：60psi.
2.2 sample preparation methods, with embodiment 4.
2.3 linear investigations
As a result show, the linear relationship in the range of 0.200-10.0ng/mL of compound 4 is good, compound 9 10.0-
Linear relationship is good in the range of 500ng/mL.
2.4 sample analysis
The sample analysis result of 3 batches, is shown in Table 14.As a result show to change in the Lapatinib bulk drug product of 3 batches
Compound 4 and compound 9 are in limit.
Table 14：Sample analysis result table
Embodiment 6
1. instrument and reagent
Reagent：Acetonitrile (Fisher), water, ammonium formate, Lapatinib bulk drug (4 batches), 4- (3- fluorobenzyloxies)-
3- chloroanilines (the lot number of compound 4：CM1101-130701-F2), 2- (methylsulfonyl) ethylamine hydrochloride (lot number of compound 9：
CM1101-130901-F2)。
Instrument：Mass spectrum：AB Sciex Q-Trap 4500, efficient liquid phase：Shimadzu 20ACXR
2. experiment content
2.1 chromatograms and Mass Spectrometry Conditions
Chromatographic condition is with system suitability using octadecyl silane as filler；Mobile phase by mobile phase A and
Mobile phase B forms, wherein, the mobile phase A is the formic acid aqueous ammonium that concentration is 5 mM/ls, and the Mobile phase B is second
Nitrile；Flow velocity 0.7ml/min；35 degrees Celsius of column temperature；The μ l of sample size 5, Detection wavelength 261nm, type of elution is gradient elution.According under
Table 15 carries out gradient elution：
Table 15
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 50 | 50 |
| 1.0 | 50 | 50 |
| 1.5 | 8 | 92 |
| 2.5 | 8 | 92 |
| 2.6 | 50 | 50 |
| 3.6 | 50 | 50 |
Connect and tested with triple level Four bar mass spectrographs, MRM patterns are monitored using multiple reaction：Impurity 4- (3- to be measured
Fluorobenzyloxy) the detection ion pairs of -3- chloroanilines is m/z:252—143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/
z:124—79；Target detection ion pair is m/z in lidocaine:235—86；Typical mass detector parameter is as follows：
Source parameters：
CUR：30psi,
IS：5500V,
TEM：550 DEG C,
GS1：50psi,
GS2：60psi.
2.2 sample preparation methods, with embodiment 4.
2.3 linear investigations
As a result show, the linear relationship in the range of 0.200-10.0ng/mL of compound 4 is good, compound 9 10.0-
Linear relationship is good in the range of 500ng/mL.
2.4 sample analysis
The sample analysis result of 4 batches, is shown in Table 16.As a result show to change in the Lapatinib bulk drug product of 4 batches
Compound 4 and compound 9 are in limit.
Table 16：Sample analysis result table
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or the spy for combining the embodiment or example description
Point is contained at least one embodiment or example of the present invention.In this manual, to the schematic representation of above-mentioned term not
Identical embodiment or example must be directed to.Moreover, specific features, structure, material or the feature of description can be with office
Combined in an appropriate manner in one or more embodiments or example.In addition, in the case of not conflicting, the skill of this area
Art personnel can be tied the different embodiments or example and the feature of different embodiments or example described in this specification
Close and combine.
Although embodiments of the invention have been shown and described above, it is to be understood that above-described embodiment is example
Property, it is impossible to limitation of the present invention is interpreted as, one of ordinary skill in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, changed, replacing and modification.
Claims (6)
1. 4- (3- fluorobenzyloxies) 3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride impurity contain in one kind detection Lapatinib
The method of amount, it is characterised in that methods described is carried out using LC-MS/MS combination detection methods；
Wherein, chromatographic condition is：
Chromatographic column is using octadecyl silane as filler；
Mobile phase is made up of mobile phase A and Mobile phase B, wherein, the mobile phase A is the ammonium formate water that concentration is 5 mM/ls
Solution, the Mobile phase B are acetonitrile；
Type of elution is gradient elution, and the condition of the gradient elution is：
Mass Spectrometry Conditions are：
Ion gun is ESI sources, is detected using positive ion mode, multiple reaction monitoring MRM patterns；
The detection ion pair of Lapatinib is m/z 581-365；The detection ion pair of 4- (3- fluorobenzyloxies) 3- chloroanilines is
m/z 252—143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/z 124-79；And the detection ion pair of lidocaine
For m/z 235-86；
Source parameters is：
Gas curtain gas 30psi；
Ion injection electric 5500V；
550 DEG C of temperature；
Ion gun GS1 50psi；
Ion gun GS2 60psi.
2. according to the method for claim 1, it is characterised in that the column temperature of the chromatographic column is 25 degrees Celsius~35 Celsius
Degree.
3. according to the method for claim 1, it is characterised in that the flow velocity of the mobile phase is 0.5ml/min~0.7ml/
min。
4. according to the method for claim 1, it is characterised in that the chromatographic column is C18 chromatographic columns.
5. according to the method for claim 1, it is characterised in that including：
(1) chromatographic condition：Using octadecyl silane as filler；The mobile phase A is the first that concentration is 5 mM/ls
Sour aqueous ammonium, the Mobile phase B are acetonitrile；Flow velocity 0.5ml/min~0.7ml/min；25 degrees Celsius~35 degrees Celsius of column temperature；
The μ l of sample size 5, Detection wavelength 261nm, are carried out according to the following table gradient elution：
(2) Mass Spectrometry Conditions：Ion gun is ESI sources, is detected using positive ion mode, multiple reaction monitoring MRM patterns；4- (3- fluorine
Benzyloxy) the detection ion pairs of -3- chloroanilines is m/z:252—143；The detection ion pair of 2- (methylsulfonyl) ethamine is m/z:
124—79；Target detection ion pair is m/z in lidocaine:235—86；
Source parameters is：
Gas curtain gas 30psi；
Ion injection electric 5500V；
550 DEG C of temperature；
Ion gun GS1 50psi；
Ion gun GS2 60psi,
(3) Lapatinib bulk drug and lidocaine internal standard are weighed respectively, are 4 with volume ratio：1 acetonitrile-aqueous solution is configured to
Lapatinib raw material concentration be 5.00mg/mL storing solution, then with volume ratio be 1：1 acetonitrile-aqueous solution is by the deposit
Liquid is diluted to the need testing solution, and in the need testing solution, the concentration of the Lapatinib bulk drug is 0.500mg/
ML, target concentration is 1.00ng/mL in the lidocaine；
(4) draw the μ l of need testing solution 5 injection LC-MS LC-MS instrument, according to the chromatographic condition described in (1) and (2) with
Mass Spectrometry Conditions are detected, and record chromatogram；
(5) according to chromatogram resulting in step (4), calibration curve method is utilized to calculate 4- in the Lapatinib bulk drug
The content of (3- fluorobenzyloxies) -3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride.
6. according to the method for claim 5, it is characterised in that the calibration curve method comprises the following steps：
(a) 4- (3- fluorobenzyloxies) -3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride are dissolved in volume ratio for 4 respectively：1
In acetonitrile-aqueous solution, the concentration for obtaining 4- (3- fluorobenzyloxies) -3- chloroanilines is 1.00mg/mL the first reference substance deposit
The concentration of liquid and 2- (methylsulfonyl) ethylamine hydrochloride is the second reference substance storing solution with 2.00mg/mL；
(b) it is 1 using volume ratio：1 acetonitrile-aqueous solution is by the first reference substance storing solution and the second reference substance deposit
Liquid is diluted, and is obtained containing 10.0 μ g/mL 4- (3- fluorobenzyloxies) -3- chloroanilines and 500 μ g/mL 2- (methylsulfonyl) second
The mixing intermediate solution 1 of amine hydrochlorate；
(c) the mixing intermediate solution 1 is diluted 100 times, obtains mixing intermediate solution 2；
(d) the mixing intermediate solution 2 is diluted 10 times, obtains mixing intermediate solution 3；
(e) lidocaine internal standard is dissolved in volume ratio for 1：In 1 acetonitrile-aqueous solution, obtaining lidocaine internal standard concentration is
0.200mg/mL internal standard storing solution, then it is 20.0ng/mL's that the internal standard storing solution is diluted into lidocaine internal standard concentration
Internal standard intermediate solution；
(f) using mixing intermediate solution 2, the mixing intermediate solution 3 and the internal standard intermediate solution, prepared according to following table
Standard curve sample：
(g) the μ l of standard curve sample solution 5 are drawn and is injected separately into LC-MS LC-MS instrument, according to described in (1) and (2)
Chromatographic condition and Mass Spectrometry Conditions are detected, and record chromatogram；
(h) using the ratio of 4- (3- fluorobenzyloxies) -3- chloroanilines and lidocaine internal standard peak area as ordinate, 4- (3- fluorine
Benzyloxy) -3- chloroanilines concentration for abscissa carry out linear regression, make the first standard curve, with 2- (methylsulfonyl) second
The ratio of amine hydrochlorate and lidocaine internal standard peak area is ordinate, and the concentration of 2- (methylsulfonyl) ethylamine hydrochloride is abscissa
Linear regression is carried out, makes the second standard curve；
(i) by 4- (3- fluorobenzyloxies) -3- chloroanilines, 2- (methylsulfonyl) ethylamine salt in chromatogram resulting in step (4)
Target peak area substitutes into first standard curve and second standard curve respectively in hydrochlorate and lidocaine, calculates
The content of 4- (3- fluorobenzyloxies) -3- chloroanilines and 2- (methylsulfonyl) ethylamine hydrochloride into the Lapatinib bulk drug.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410755906.4A CN105738492B (en) | 2014-12-10 | 2014-12-10 | The method of impurity content in LC MS/MS combination measure Lapatinibs |
| PCT/CN2015/070901 WO2016090730A1 (en) | 2014-12-10 | 2015-01-16 | Method for determining content of impurities in lapatinib by using lc-ms/ms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410755906.4A CN105738492B (en) | 2014-12-10 | 2014-12-10 | The method of impurity content in LC MS/MS combination measure Lapatinibs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105738492A CN105738492A (en) | 2016-07-06 |
| CN105738492B true CN105738492B (en) | 2017-12-19 |
Family
ID=56106524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410755906.4A Expired - Fee Related CN105738492B (en) | 2014-12-10 | 2014-12-10 | The method of impurity content in LC MS/MS combination measure Lapatinibs |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105738492B (en) |
| WO (1) | WO2016090730A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106932522A (en) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | The assay method of impurity compound I contents in a kind of nilotinib |
| CN112782296B (en) * | 2020-12-24 | 2023-01-20 | 上海微谱检测科技集团股份有限公司 | Method for detecting extract in anticancer drug by adopting liquid chromatography-mass spectrometer |
| CN112903856B (en) * | 2021-01-22 | 2023-02-17 | 青岛农业大学 | Pretreatment method for detecting trace chloroformyl compound in water sample and application thereof |
| CN114594192A (en) * | 2022-03-07 | 2022-06-07 | 山东大学 | Method for detecting chloroaniline and chloronitroaniline isomers in posaconazole starting material |
| CN115993414A (en) * | 2023-01-18 | 2023-04-21 | 中汽研汽车零部件检验中心(宁波)有限公司 | Method for determining amine substances of automobile nonmetallic material |
| CN116068117B (en) * | 2023-01-28 | 2023-06-16 | 北京大学 | High-throughput detection method for alkyl resorcinol homolog based on liquid chromatography-mass spectrometry |
| CN116106455B (en) * | 2023-03-28 | 2023-07-25 | 上海赛默罗生物科技有限公司 | Method for detecting related substances in substituted nicotinamide medicines |
| CN116297974A (en) * | 2023-03-30 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | Method for simultaneously detecting concentration of lidocaine and metabolites MEGX and salbutamol in blood plasma |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017387A3 (en) * | 2008-08-06 | 2010-05-14 | Teva Pharmaceutical Industries Ltd. | Lapatinib, salts thereof, processes and intermediates for their preparation |
| EP2358666A1 (en) * | 2008-11-03 | 2011-08-24 | Natco Pharma Limited | A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| CN103339509A (en) * | 2011-01-28 | 2013-10-02 | 佰欧迪塞克斯公司 | Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy |
| WO2014165506A1 (en) * | 2013-04-01 | 2014-10-09 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treament of pancreatic cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20110894A1 (en) * | 2011-05-20 | 2012-11-21 | Italiana Sint Spa | IMPACT OF THE LAPATINIB AND ITS SALTS |
-
2014
- 2014-12-10 CN CN201410755906.4A patent/CN105738492B/en not_active Expired - Fee Related
-
2015
- 2015-01-16 WO PCT/CN2015/070901 patent/WO2016090730A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017387A3 (en) * | 2008-08-06 | 2010-05-14 | Teva Pharmaceutical Industries Ltd. | Lapatinib, salts thereof, processes and intermediates for their preparation |
| EP2358666A1 (en) * | 2008-11-03 | 2011-08-24 | Natco Pharma Limited | A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts |
| CN103339509A (en) * | 2011-01-28 | 2013-10-02 | 佰欧迪塞克斯公司 | Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy |
| WO2014165506A1 (en) * | 2013-04-01 | 2014-10-09 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treament of pancreatic cancer |
Non-Patent Citations (4)
| Title |
|---|
| Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products;Saadat, Ebrahim; Kelishady, Pooya Dehghan; Ravar, Fatemeh;《JOURNAL OF CHROMATOGRAPHIC SCIENCE》;20171009;第53卷(第6期);932-939 * |
| HPLC法测定二甲苯磺酸拉帕替尼含量及其有关物质;仲艳;《中国药师》;20131130;第16卷(第11期);1672-1675 * |
| HPLC法测定二甲苯磺酸拉帕替尼片中拉帕替尼的含量;徐家根;《中国药房》;20120915;第23卷(第37期);3524-3525 * |
| 高效液相色谱法测定二甲苯磺酸拉帕替尼片有关物质;刘俊华;《中国药学杂志》;20130430;第48卷(第8期);644-648 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105738492A (en) | 2016-07-06 |
| WO2016090730A1 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105738492B (en) | The method of impurity content in LC MS/MS combination measure Lapatinibs | |
| CN108780075A (en) | The high-sensitivity analysis method of Imatinib gene impurity | |
| CN107328871A (en) | Ao Xi replaces the drug concentration of Buddhist nun in UPLC MS/MS combinations detection human plasma and/or cerebrospinal fluid | |
| CN105717237B (en) | The detection method of GABA, Glu, DA, 5-HT and Capillary zone electropheresis in a kind of serum | |
| CN104122363A (en) | Measuring method of mecobalamin tablet related substance | |
| Yi et al. | Simultaneous determination of norfloxacin and lomefloxacin in milk by first derivative synchronous fluorescence spectrometry using Al (III) as an enhancer | |
| Wang et al. | Development and validation of a hydrophilic interaction ultra‐high‐performance liquid chromatography with triple quadrupole MS/MS for the absolute and relative quantification of amino acids in Sophora alopecuroides L. | |
| CN108152418A (en) | The HPLC detection methods of ketorolac tromethamine or/and impurity in ketorolac tromethamine or its preparation | |
| Sankar et al. | Development and validation of novel UV and RP-HPLC methods for determination of cilnidipine (a new generation ca channel blocker) in pharmaceutical dosage form | |
| CN110243963A (en) | A kind of LC-MS/MS detection method of Captopril in Human Plasma | |
| Baokar et al. | Validation of simple and rapid UV-spectrophotometric method with stress degradation study for sildenafil citrate | |
| CN103558174B (en) | A kind of method utilizing cresol content in determined by ultraviolet spectrophotometry Lysol | |
| Tatar Ulu | High Performance Liquid Chromatography for the Determination of Metoclopramide in Pharmaceutical Preparations Using Pre‐column Derivatization with Fluorescamine | |
| CN105158372A (en) | Method for determining urocanic acid and ethyl ester thereof in cosmetics | |
| CN105572264B (en) | UPLC-MS/MS methods measure his the luxuriant and rich with fragrance concentration for replacing Buddhist nun and active metabolite SCR868 in human plasma | |
| KR20200056019A (en) | Biomarker for the discrimination of geographical origins of the soybeans and method for discriminating of geographical origin using the same | |
| Gong et al. | Holistic quality evaluation of compound liquorice tablets using capillary electrophoresis fingerprinting combined with chemometric Methods | |
| Hasin et al. | Validation of high performance liquid chromatography (HPLC) method for determination of erlotinib related substance in pharmaceutical dosage form | |
| CN102841169A (en) | Method for measuring calcium levofolinate-related substances by using high performance liquid chromatography gradient method | |
| CN106596750B (en) | Six kinds of content assaying methods in relation to substance in a kind of otoginsenoside preparation of sodium | |
| Amanlou et al. | Simple extractive colorimetric determination of buspirone by acid-dye complexation method in solid dosage form | |
| Saraya et al. | Applicability of fluorescamine as a fluorogenic reagent for highly sensitive fluorimetric analysis of the tyrosine kinase inhibitor (avapritinib) in pharmaceuticals and biological samples | |
| CN106404925A (en) | Method for determining six barbiturates in human whole blood | |
| CN111175392B (en) | Quality control method of cough-relieving loquat syrup | |
| CN105403648A (en) | Method for detecting illegally-added fluoxetine in product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190731 Address after: 430075 C7 Building, 666 High-tech Avenue, Donghu High-tech Development Zone, Wuhan City, Hubei Province Patentee after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Address before: 430075 No. 666, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan Patentee before: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171219 |